Detalles de la búsqueda
1.
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
Cancer Immunol Immunother
; 73(3): 47, 2024 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38349411
2.
Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy.
J Biomed Sci
; 31(1): 17, 2024 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38281981
3.
Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
Cancer
; 129(24): 3873-3883, 2023 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37538036
4.
Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
BMC Cancer
; 23(1): 206, 2023 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36870951
5.
Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency.
Cell Commun Signal
; 21(1): 48, 2023 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36869329
6.
Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities.
Pharmacol Res
; 194: 106844, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37392900
7.
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
Cancer Immunol Immunother
; 71(7): 1681-1691, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34817638
8.
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
BMC Med
; 20(1): 453, 2022 11 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36424628
9.
Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study.
BMC Med
; 20(1): 12, 2022 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35039026
10.
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
BMC Med
; 20(1): 277, 2022 08 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36031613
11.
Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.
BMC Cancer
; 22(1): 514, 2022 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35525919
12.
ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
Cell Commun Signal
; 20(1): 156, 2022 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36229854
13.
ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer.
Mol Med
; 27(1): 138, 2021 10 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34715776
14.
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer.
J Cell Mol Med
; 23(10): 6812-6821, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31393074
15.
Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment.
Chin J Cancer Res
; 31(2): 349-356, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31156305
16.
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study.
Chin J Cancer Res
; 31(3): 481-488, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31354217
17.
Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
BMC Immunol
; 19(1): 14, 2018 04 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29661145
18.
Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
Ann Hematol
; 96(9): 1477-1483, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28695246
19.
[Clinicopathological characteristics and prognostic analysis of primary intestinal diffuse large B-cell lymphoma].
Zhonghua Yi Xue Za Zhi
; 95(48): 3895-8, 2015 Dec 19.
Artículo
en Zh
| MEDLINE | ID: mdl-27122208
20.
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing.
Expert Rev Anticancer Ther
; 24(3-4): 183-192, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526910